AR037131A1 - Formulaciones de jarabe de ribavirina - Google Patents
Formulaciones de jarabe de ribavirinaInfo
- Publication number
- AR037131A1 AR037131A1 ARP020104108A ARP020104108A AR037131A1 AR 037131 A1 AR037131 A1 AR 037131A1 AR P020104108 A ARP020104108 A AR P020104108A AR P020104108 A ARP020104108 A AR P020104108A AR 037131 A1 AR037131 A1 AR 037131A1
- Authority
- AR
- Argentina
- Prior art keywords
- ribavirina
- syrup formulations
- ribavirin
- pharmaceutically acceptable
- liquid formulation
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
- A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/7056—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing five-membered rings with nitrogen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Molecular Biology (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Virology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Gastroenterology & Hepatology (AREA)
- Biochemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
Formulación líquida que comprende ribavirina que tiene una vida de estantería más larga y sabor mejorado. Reivindicación 1: Una fórmula líquida que comprende ribavirina; un sistema de tamponamiento, encontrándose el pH de la formulación líquida en el orden de desde aproximadamente 4,8 a aproximadamente 5,3; por lo menos un agente edulcorante farmacéuticamente aceptable; y por lo menos un agente que incrementa la viscosidad farmacéuticamente aceptable
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US33475101P | 2001-10-31 | 2001-10-31 |
Publications (1)
Publication Number | Publication Date |
---|---|
AR037131A1 true AR037131A1 (es) | 2004-10-20 |
Family
ID=23308655
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP020104108A AR037131A1 (es) | 2001-10-31 | 2002-10-29 | Formulaciones de jarabe de ribavirina |
Country Status (27)
Country | Link |
---|---|
US (1) | US6790837B2 (es) |
EP (1) | EP1480653B1 (es) |
JP (1) | JP4393192B2 (es) |
KR (1) | KR100929320B1 (es) |
CN (1) | CN1319535C (es) |
AR (1) | AR037131A1 (es) |
AT (1) | ATE439847T1 (es) |
AU (1) | AU2002350081B2 (es) |
BR (1) | BR0213536A (es) |
CA (1) | CA2464151C (es) |
CO (1) | CO5570681A2 (es) |
CY (1) | CY1110524T1 (es) |
DE (1) | DE60233438D1 (es) |
DK (1) | DK1480653T3 (es) |
ES (1) | ES2330419T3 (es) |
HK (1) | HK1066719A1 (es) |
HU (1) | HU229259B1 (es) |
MX (1) | MXPA04004068A (es) |
NO (1) | NO334361B1 (es) |
NZ (1) | NZ531967A (es) |
PE (1) | PE20030545A1 (es) |
PL (1) | PL205342B1 (es) |
PT (1) | PT1480653E (es) |
SI (1) | SI1480653T1 (es) |
TW (1) | TWI259082B (es) |
WO (1) | WO2003037312A2 (es) |
ZA (1) | ZA200402975B (es) |
Families Citing this family (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES2373042T3 (es) * | 2003-10-08 | 2012-01-30 | Mallinckrodt Llc | Solución de metilfenidato y procedimientos de administración y producción asociados. |
US20060110479A1 (en) * | 2004-11-24 | 2006-05-25 | Mitra Shankar K | Natural composition for curing hepatitis-B, methods for making the same and pharmaceutical formulations thereof |
EP2178503A1 (en) * | 2007-07-12 | 2010-04-28 | Novartis Ag | Oral pharmaceutical solutions containing telbivudine |
GB2506086A (en) | 2011-10-21 | 2014-03-19 | Abbvie Inc | Methods for treating HCV comprising at least two direct acting antiviral agent, ribavirin but not interferon |
CA2811250C (en) | 2011-10-21 | 2015-08-11 | Abbvie Inc. | Methods for treating hcv |
US8466159B2 (en) | 2011-10-21 | 2013-06-18 | Abbvie Inc. | Methods for treating HCV |
US8492386B2 (en) | 2011-10-21 | 2013-07-23 | Abbvie Inc. | Methods for treating HCV |
WO2013149258A2 (en) | 2012-03-30 | 2013-10-03 | Charles Drew University of Medicine and Science | Compositions and methods for treating or preventing metabolic syndrome disorders |
US20140271923A1 (en) | 2013-03-14 | 2014-09-18 | Christopher Brian Reid | Compositions & formulations for preventing and treating chronic diseases that cluster in patients such as cardiovascular disease, diabetes, obesity, polycystic ovary syndrome, hyperlipidemia and hypertension, as well as for preventing and treating other diseases and conditions |
US11192914B2 (en) | 2016-04-28 | 2021-12-07 | Emory University | Alkyne containing nucleotide and nucleoside therapeutic compositions and uses related thereto |
US20190336443A1 (en) * | 2018-05-03 | 2019-11-07 | Navinta Iii Inc | Ready-To-Use Liquid Parenteral Formulations Of Ribavirin |
CN109568257A (zh) * | 2018-12-24 | 2019-04-05 | 江西润泽药业有限公司 | 一种利巴韦林注射液及其制备方法 |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4211771A (en) * | 1971-06-01 | 1980-07-08 | Robins Ronald K | Treatment of human viral diseases with 1-B-D-ribofuranosyl-1,2,4-triazole-3-carboxamide |
JPS58198416A (ja) * | 1982-05-15 | 1983-11-18 | Ota Seiyaku Kk | セフアレキシンドライシロツプ剤の製造法 |
JPS63177797A (ja) * | 1987-01-19 | 1988-07-21 | Ajinomoto Co Inc | リボ−ス−1−リン酸及びリバビリンの製造法 |
US4880784A (en) * | 1987-12-21 | 1989-11-14 | Brigham Young University | Antiviral methods utilizing ribofuranosylthiazolo[4,5-d]pyrimdine derivatives |
EP0758237B1 (en) * | 1994-04-28 | 2003-08-27 | Bionumerik Pharmaceuticals, Inc. | Lactone stable formulation of camptothecin or 7-ethyl camptothecin in dimethylisosorbide or dimethylacetamide |
US5767097A (en) * | 1996-01-23 | 1998-06-16 | Icn Pharmaceuticals, Inc. | Specific modulation of Th1/Th2 cytokine expression by ribavirin in activated T-lymphocytes |
US6423695B1 (en) * | 1998-01-13 | 2002-07-23 | Ribapharm, Inc. | Cytokine related treatments of disease |
US6132758A (en) * | 1998-06-01 | 2000-10-17 | Schering Corporation | Stabilized antihistamine syrup |
-
2002
- 2002-10-29 AR ARP020104108A patent/AR037131A1/es active IP Right Grant
- 2002-10-29 PE PE2002001063A patent/PE20030545A1/es not_active Application Discontinuation
- 2002-10-30 TW TW091132150A patent/TWI259082B/zh not_active IP Right Cessation
- 2002-10-31 CA CA2464151A patent/CA2464151C/en not_active Expired - Fee Related
- 2002-10-31 EP EP02786612A patent/EP1480653B1/en not_active Expired - Lifetime
- 2002-10-31 DK DK02786612T patent/DK1480653T3/da active
- 2002-10-31 DE DE60233438T patent/DE60233438D1/de not_active Expired - Lifetime
- 2002-10-31 US US10/285,119 patent/US6790837B2/en not_active Expired - Lifetime
- 2002-10-31 PL PL372224A patent/PL205342B1/pl not_active IP Right Cessation
- 2002-10-31 PT PT02786612T patent/PT1480653E/pt unknown
- 2002-10-31 SI SI200230853T patent/SI1480653T1/sl unknown
- 2002-10-31 AU AU2002350081A patent/AU2002350081B2/en not_active Ceased
- 2002-10-31 ES ES02786612T patent/ES2330419T3/es not_active Expired - Lifetime
- 2002-10-31 MX MXPA04004068A patent/MXPA04004068A/es active IP Right Grant
- 2002-10-31 NZ NZ531967A patent/NZ531967A/en not_active IP Right Cessation
- 2002-10-31 AT AT02786612T patent/ATE439847T1/de active
- 2002-10-31 JP JP2003539656A patent/JP4393192B2/ja not_active Expired - Fee Related
- 2002-10-31 BR BR0213536-1A patent/BR0213536A/pt not_active IP Right Cessation
- 2002-10-31 WO PCT/US2002/034898 patent/WO2003037312A2/en active IP Right Grant
- 2002-10-31 HU HU0600300A patent/HU229259B1/hu unknown
- 2002-10-31 KR KR1020047005865A patent/KR100929320B1/ko not_active IP Right Cessation
- 2002-10-31 CN CNB028217233A patent/CN1319535C/zh not_active Expired - Fee Related
-
2004
- 2004-04-19 ZA ZA2004/02975A patent/ZA200402975B/en unknown
- 2004-04-27 CO CO04038162A patent/CO5570681A2/es active IP Right Grant
- 2004-05-28 NO NO20042228A patent/NO334361B1/no not_active IP Right Cessation
- 2004-12-04 HK HK04109613.4A patent/HK1066719A1/xx not_active IP Right Cessation
-
2009
- 2009-10-29 CY CY20091101125T patent/CY1110524T1/el unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DE69910230D1 (de) | Paclitaxel enthaltende arzneimittel | |
DE60236541D1 (de) | Inhibitoren von 11-beta-hydroxysteroiddehydrogenase typ 1 | |
CO5660273A2 (es) | Formulaciones de proteina y anticuerpo de alta concentracion | |
BR0207930A (pt) | Composições farmacêuticas lìquidas com sabor mascarado | |
AR037131A1 (es) | Formulaciones de jarabe de ribavirina | |
EP2263651A3 (en) | Low viscosity liquid dosage forms | |
UY27465A1 (es) | Métodos y composiciones para tratar flavivirus y pestivirus con 4' modificaciones nucleosides | |
CU23536A3 (es) | Estabilizador de interleuquina 2 | |
BR0207961A (pt) | Combinação de análogos da epotilona e agentes quimioterápicos para o tratamento de doenças proliferativas | |
CO5231147A1 (es) | Composicion congelante | |
RS49764B (sr) | Farmaceutski preparat za primenu na mukozu | |
IT1318649B1 (it) | Composizioni farmaceutiche per il trattamento di mucositi e stomatiti. | |
MXPA05008909A (es) | Formulacion intranasal de rotigotina. | |
ATE333290T1 (de) | Zusammensetzungen für die freisetzung von protein auf dem pulmonalen weg | |
DE60104206D1 (de) | Halbfeste arzneizubereitung enthaltend isotretinoin | |
AP2003002907A0 (en) | Liquid pharmaceutical composition. | |
PE20021017A1 (es) | Composicion parenteral reconstituible | |
MXPA02010648A (es) | Formulaciones liquidas. | |
DE69912262D1 (de) | Retinolhaltiges arzneimittel kompatibel mit weichgelatinekapseln | |
NZ560648A (en) | Formulation for aviptadil (vasoactive intestinal peptide, VIP) | |
RS50310B (sr) | Farmaceutska kompozicija koja sadrži ciklesonid za primenu na sluzokoži | |
AR024959A1 (es) | Una composicion farmaceutica liquida basada en paracetamol | |
BR0005332A (pt) | Aroma encapsulado | |
ITRM20030363A1 (it) | Composizioni comprendenti la 3, 5diiodotironina e uso farmaceutico di esse. | |
WO2004039326A3 (en) | Propofol with cysteine |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FG | Grant, registration | ||
FG | Grant, registration |